Literature DB >> 19828608

The poxvirus A35 protein is an immunoregulator.

Kristina E Rehm1, Gwendolyn J B Jones, Alice A Tripp, Mark W Metcalf, Rachel L Roper.   

Abstract

It was shown previously that the highly conserved vaccinia virus A35 gene is an important virulence factor in respiratory infection of mice. We show here that A35 is also required for full virulence by the intraperitoneal route of infection. A virus mutant in which the A35 gene has been removed replicated normally and elicited improved antibody, gamma interferon-secreting cell, and cytotoxic T-lymphocyte responses compared to wild-type virus, suggesting that A35 increases poxvirus virulence by immunomodulation. The enhanced immune response correlated with an improved control of viral titers in target organs after the development of the specific immune response. Finally, the A35 deletion mutant virus also provided protection from lethal challenge (1,000 50% lethal doses) equal to that of the wild-type virus. Together, these data suggest that A35 deletion viruses will make safer and more efficacious vaccines for poxviruses. In addition, the A35 deletion viruses will serve as improved platform vectors for other infectious diseases and cancer and will be superior vaccine choices for postexposure poxvirus vaccination, as they also provide improved kinetics of the immune response.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19828608      PMCID: PMC2798446          DOI: 10.1128/JVI.01802-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Tanapox infection in a college student.

Authors:  A Damian Dhar; Andrew E Werchniak; Yu Li; Jeoffry B Brennick; Cynthia S Goldsmith; Richard Kline; Inger Damon; Sidney N Klaus
Journal:  N Engl J Med       Date:  2004-01-22       Impact factor: 91.245

2.  CD8+ T cell cross-priming via transfer of proteasome substrates.

Authors:  Christopher C Norbury; Sameh Basta; Keri B Donohue; David C Tscharke; Michael F Princiotta; Peter Berglund; James Gibbs; Jack R Bennink; Jonathan W Yewdell
Journal:  Science       Date:  2004-05-28       Impact factor: 47.728

Review 3.  Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination.

Authors:  Robert E Eckart; Suzanne S Love; J Edwin Atwood; Mark K Arness; Dimitri C Cassimatis; Charles L Campbell; Sheri Y Boyd; Joseph G Murphy; David L Swerdlow; Limone C Collins; James R Riddle; David N Tornberg; John D Grabenstein; Renata J M Engler
Journal:  J Am Coll Cardiol       Date:  2004-07-07       Impact factor: 24.094

4.  Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox.

Authors:  J W Hooper; E Thompson; C Wilhelmsen; M Zimmerman; M Ait Ichou; S E Steffen; C S Schmaljohn; A L Schmaljohn; P B Jahrling
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

5.  Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.

Authors:  Linda S Wyatt; Patricia L Earl; Leigh Anne Eller; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-11       Impact factor: 11.205

6.  Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.

Authors:  Igor M Belyakov; Patricia Earl; Amiran Dzutsev; Vladimir A Kuznetsov; Michael Lemon; Linda S Wyatt; James T Snyder; Jeffrey D Ahlers; Genoveffa Franchini; Bernard Moss; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-17       Impact factor: 11.205

7.  Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity.

Authors:  Patrick C Reading; Geoffrey L Smith
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

8.  Vaccinia virus decreases major histocompatibility complex (MHC) class II antigen presentation, T-cell priming, and peptide association with MHC class II.

Authors:  Kristina E Rehm; Ramsey F Connor; Gwendolyn J B Jones; Kenneth Yimbu; Mark D Mannie; Rachel L Roper
Journal:  Immunology       Date:  2009-11       Impact factor: 7.397

9.  Re-emergence of human monkeypox in Zaire in 1996. Monkeypox Epidemiologic Working Group.

Authors:  V B Mukinda; G Mwema; M Kilundu; D L Heymann; A S Khan; J J Esposito
Journal:  Lancet       Date:  1997-05-17       Impact factor: 202.731

10.  Cellular and humoral immunity against vaccinia virus infection of mice.

Authors:  Rong Xu; Aaron J Johnson; Denny Liggitt; Michael J Bevan
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

View more
  9 in total

1.  Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching.

Authors:  Kristina E Rehm; Rachel L Roper
Journal:  Vaccine       Date:  2011-02-23       Impact factor: 3.641

2.  Antigen presentation assays to investigate uncharacterized immunoregulatory genes.

Authors:  Rachel L Roper
Journal:  Methods Mol Biol       Date:  2012

3.  Gene amplification acts as a molecular foothold to facilitate cross-species adaptation and evasion of multiple antiviral pathways.

Authors:  Shefali Banerjee; Cathy Smith; Adam Geballe; Stefan Rothenburg; Jacob O Kitzman; Greg Brennan
Journal:  bioRxiv       Date:  2022-06-08

4.  Vaccinia virus A35R inhibits MHC class II antigen presentation.

Authors:  Kristina E Rehm; Ramsey F Connor; Gwendolyn J B Jones; Kenneth Yimbu; Rachel L Roper
Journal:  Virology       Date:  2009-12-02       Impact factor: 3.616

5.  Attenuation of vaccinia Tian Tan strain by removal of viral TC7L-TK2L and TA35R genes.

Authors:  Shifu Kan; Yuhang Wang; Lili Sun; Peng Jia; Yanxin Qi; Jiaqiang Su; Lei Liu; Guohua Yang; Liming Liu; Zhuoyue Wang; Jinhui Wang; Guangchen Liu; Ningyi Jin; Xiao Li; Zhuang Ding
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

6.  The effects of diets enriched in omega-3 polyunsaturated fatty acids on systemic vaccinia virus infection.

Authors:  Gwendolyn J B Jones; Rachel L Roper
Journal:  Sci Rep       Date:  2017-11-22       Impact factor: 4.379

Review 7.  Modulating Vaccinia Virus Immunomodulators to Improve Immunological Memory.

Authors:  Jonas D Albarnaz; Alice A Torres; Geoffrey L Smith
Journal:  Viruses       Date:  2018-02-28       Impact factor: 5.048

8.  Enhancing the Immunogenicity of Vaccinia Virus.

Authors:  Sergei N Shchelkunov; Stanislav N Yakubitskiy; Alexander A Sergeev; Ekaterina V Starostina; Ksenia A Titova; Stepan A Pyankov; Galina A Shchelkunova; Mariya B Borgoyakova; Alexey M Zadorozhny; Lyubov A Orlova; Denis N Kisakov; Larisa I Karpenko
Journal:  Viruses       Date:  2022-06-30       Impact factor: 5.818

9.  Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer.

Authors:  Michael White; Andrew Freistaedter; Gwendolyn J B Jones; Emmanuel Zervos; Rachel L Roper
Journal:  PLoS One       Date:  2018-02-23       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.